| Disease | THE OBJECTIVES WERE TO ASSESS THE EFFICACY OF COLCHICINE EVALUATED IN RANDOMIZED TRIALS ON MORTALITY, LIVER RELATED COMPLICATIONS,LIVER FIBROSIS MARKERS, LIVER HISTOL, ALC. CONSUMPTION, QUALITY OF LIFE, AND HEALTH ECONOMICS IN PATIENTS WITH ALC.
AND NON-ALC. FIBROSIS OR CIRRHOSIS. COMBINING THE RESULTS OF 14 RANDOMIZED CLIN TRIALS INCLUDING 1138 PATIENTS DEMONSTRATED NO SIGNIFICANT EFFECTS OF COLCHICINE ON MORTALITY, LIVER RELATED MORTALITY, COMPLICATIONS, AND THE OTHER OUTCOMES.
COLCHICINE WAS ASSOCD WITH A SIGNIFICANTLY INCREASED RISK OF ADVERSE EVENTS, SHOULD NOT BE USED FOR LIVER FIBROSIS OR LIVER CIRRHOSIS IRRESP. OF ETIOL. |